Clinical research company Medpace Holdings (NASDAQ:MEDP) will be reporting earnings this Wednesday after the bell. Here’s ...

Over the past six months, Medpace’s shares (currently trading at $483.21) have posted a disappointing 11.2% loss while the S&P 500 was down 5.5%. This might have investors contemplating their next ...

Medpace has a strong financial position with high profit margins and low debt, and it has grown at a fast rate in the last five years. The company expects headwinds in 2025 in that it foresees that ...

For this year, Medpace expects that its revenues will increase by 17.1%, which is an excellent growth rate. From 2019 to Q2 2025, Medpace's outstanding common shares declined by 22.16%, creating value ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Clinical research company Medpace Holdings (NASDAQ:MEDP) reported Q4 CY2025 results , with sales up 32% year on year to $708.5 million. The company expects the full year’s revenue to be around $2.81 ...

Total revenue was up 9.3% on a year-over-year basis. New business awards totaled $500 million in the quarter, down 18.8% year-over-year. The company ended the period with a backlog of approximately $2 ...